Outcomes of cancer treatment for technology assessment and cancer treatment guidelines

Journal of Clinical Oncology

Volumn 14, Issue 2, 1996, Pages 671-679

  Fetting, John ^a   Anderson, Paul ^a   Ball, Harrison ^a   Benear, John ^a   Benjamin, Katy ^a   Bennett, Charles ^a   Braun, Susan ^a   Brereton, Harmar ^a   Burrows, John ^a   Cobau, Charles ^a   Cohen, Alfred ^a   Ford, Leslie ^a   Friedman, Michael ^a   Ganz, Patricia ^a   Gelber, Richard ^a   Grier, Holcombe ^a   Hanks, Gerald ^a   Justice, Robert ^a   Legant, Patricia ^a   Levine, Mark ^a   Parsons, Susan ^a   Raich, Peter ^a   Schafer, Sandra ^a   Smith, Thomas ^a   Smyth, Collier ^a   Van Oosterom, A T ^a   Wade, James ^a   Weeks, Jane ^a   Winn, Rodger ^a   Woodcock, Janet ^a   more..

^a AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

BIOMEDICAL TECHNOLOGY ASSESSMENT; CANCER SURVIVAL; CANCER THERAPY; CLINICAL RESEARCH; COST EFFECTIVENESS ANALYSIS; DRUG TOXICITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

EID: 9044233642     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.2.671     Document Type: Review

References (46)

1. Smith TJ Hillner BE, Desch CE: Commentary. Efficacy and cost-effectiveness of cancer treatment: Rational allocation of resources based on decision analysis. J Natl Cancer Inst 85:1460-1474, 1993
2. Rubin HR, Gandek B, Rogers WH, et al: Patients' ratings of outpatient visits in different practice settings. JAMA 270:835-840, 1993
3. O'Shaughnessy JA, Wittes RE, Burke G, et al: Commentary concerning demonstration of safety and efficacy of investigational anticancer agents in clinical trials. J Clin Oncol 9:2225-2232, 1991
4. Gaynon PS, Steinherz PG, Bleyer WA, et al: Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: A follow-up report of the Children's Cancer Group Study CCG-106. J Clin Oncol 11:2234-2242, 1993
5. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339:1-15, 71-85, 1992
6. Grilli R, Oxman AD, Julian JA: Chemotherapy for advanced non-small cell lung cancer: How much benefit is enough? J Clin Oncol 11:1866-1872, 1993
7. Souquet PJ, Chauvin F, Boissel JP, et al: Polychemotherapy in advanced non-small cell lung cancer: A meta-analysis. Lancet 342:19-21, 1993
8. Weinstein MC, Fineberg HV, Elstein AS, et al: Clinical Decision Analysis. Philadelphia, PA, Saunders, 1980, pp 184-227
9. Detsky AS, Naglie IG: A clinician's guide to cost-effectiveness analysis. Ann Intern Med 113:147-154, 1990
10. Goldhirsch A, Gelber R, Simes RJ, et al: Costs and benefits of adjuvant therapy in breast cancer: A quality-adjusted survival analysis. J Clin Oncol 7:36-44, 1989
11. Gelber RD, Goldhirsch A, Cavalli F: Quality-of-life-adjusted evaluation of adjuvant therapies for operable breast cancer. Ann Intern Med 114:621-628, 1991
12. Moinpour CM, Feigl P, Metch B, et al: Quality of life end points in cancer clinical trials: Review and recommendations. J Natl Cancer Inst 81:485-495, 1989
13. Donovan K, Sanson-Fisher RW, Redman S: Measuring quality of life in cancer patients. J Clin Oncol 7:959-968, 1989
14. Nayfield SG, Hailey BJ (eds): Report of the Workshop on Quality of Life Research in Cancer Clinical Trials. Bethesda, MD, National Institute of Health, 1990
15. Gill TM, Feinstein AR: A critical appraisal of the quality of quality of life measurements. JAMA 272:619-622, 1994
16. Guyatt GH, Cook DJ: Health status, quality of life, and the individual. JAMA 272:630-631, 1994
17. Slevin ML, Plant H, Lynch D, et al: Who should measure quality of life, the doctor or the patient? Br J Cancer 57:109-112, 1988
18. Skeel RT: Quality of life dimensions that are most important to cancer patients. Oncology 7:55-61, 1993
19. Sutherland HJ, Lockwood GA, Boyd NF: Ratings of the importance of quality of life variables: Therapeutic implications for patients with metastatic breast cancer. J Clin Epidemiol 43:661-666, 1990
20. Guyatt G, Walter S, Norman G: Measuring change over time: Assessing the usefulness of evaluative instruments. J Chron Dis 40:171-178, 1987
21. Guyatt GH, Bombardier C, Tugwell PX: Measuring disease-specific quality of life in clinical trials. Can Med Assoc J 134:889-895, 1986
22. Levine MN, Guyatt GH, Gent M, et al: Quality of life in stage II breast cancer: An instrument for clinical trials. J Clin Oncol 6:1798-1810, 1988
23. Cella DF, Tulsky DS, Gray G, et al: The functional assessment of cancer therapy scale: Development and validation of the general measure. J Clin Oncol 11:570-579, 1993
24. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
25. Ganz PA, Coscarelli-Schag CA, Cheng H: Assessing the quality of life - A study in newly-diagnosed breast cancer patients. J Clin Epidemiol 43:75-86, 1990
26. McCorkle R: The measurement of symptom distress. Semin Oncol Nurs 3:248-256, 1987
27. Leventhal BG, Wittes RE: Research Methods in Clinical Oncology. Treatment Toxicity and Quality of Life, vol 3. New York, NY, Raven, 1988, pp 23-40
28. Morrow GR: The assessment of nausea and vomiting: Past problems, current issues, and suggestions for future research. Cancer 53:2267-2278, 1984 (suppl)
29. Perry MC (ed): The Chemotherapy Source Book. Baltimore, MD, Williams & Wilkins, 1992, pp 276-300
30. DeVita VT: Principles of chemotherapy, in Cancer: Principles and Practice of Oncology (ed 3). Philadelphia, PA, Lippincott, 1989, pp 276-300
31. Simon RM: Design and conduct of clinical trials, in DeVita VT, Hellman S, Rosenberg SA, (eds): Cancer: Principles and Practice of Oncology (ed 3). Philadelphia, PA, Lippincott, 1989, pp 396-420
32. Coates A, Gebski V, Stat M, et al: Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med 317:1490-1495, 1987
33. Baum M, Priestman T, West RR, et al: A comparison of subjective responses in a trial comparing endocrine with cytotoxic treatment in advanced carcinoma of the breast, in Mouridsen HT, Palshof T (eds): 1 Breast Cancer: Experimental and Clinical Aspects. Proceedings of the Second EORTC Breast Cancer Working Conference. Oxford, United Kingdom, Pergammon, 1980, pp 223-226
34. Bakker W, van Oosterom AT, Aaronson NK, et al: Vindesine, platinum and bleomycin combination in non-small cell lung cancer: Survival and quality of life. Br J Cancer Oncol 22:963-970, 1986
35. Geddes DM, Dones L, Hill E, et al: Quality of life during chemotherapy for small cell lung cancer: Assessment and use of a daily diary card in a randomized trial. Eur J Cancer 26:484-492, 1990
36. Moertel CG, Hanley JA: The effect of measuring error on the results of therapeutic trials in advanced cancer. Cancer 38:388-394, 1976
37. Warr D, McKinney S, Tannock I: Influence of measurement error on assessment of response to anticancer chemotherapy: Proposal for new criteria of tumor response. J Clin Oncol 2:1040-1046, 1984
38. Einhorn LH, Crawford ED, Shipley WU, et al: Cancer of the testes, in DeVita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 3). Philadelphia, PA, Lippincott, 1989, pp 1071-1098
39. Petros JA, Andriole GL: Serum PSA after antiandrogen therapy. Urol Clin North Am 20:749-756, 1993
40. Ritter MA, Messing EM, Shanahan TG, et al: Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. J Clin Oncol 10:1208-1217, 1992
41. Jacobs I, Bast RC: The CA 125 tumour-associated antigen: A review of the literature. Hum Reprod 4:1-12, 1989
42. Tondini C, Hayes DF, Gelman R, et al: Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Cancer Res 48:4107-4112, 1989
43. Bennett CL, Armitage JL, Buchner D, et al: Economic analysis in phase III trials in cancer. Cancer Invest 12:336-342, 1994
44. Slevin ML, Stubbs L, Plant H, et al: Attitudes to chemotherapy: Comparing views of patients with those of doctors, nurses, and the general public. Br Med J 300:1458-1460, 1990
45. Early Breast Cancer Trialists Collaborative Group: Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: An overview of 61 randomized trials among 28,869 women. N Engl J Med 319:1681-1692, 1988
46. Desch CE, Hillner BE, Smith TJ, et al: Should the elderly receive chemotherapy for node-negative breast cancer? A cost-effectiveness analysis examining total and active life-expectancy outcomes. J Clin Oncol 11:777-782, 1993